

Nr	Titlu articol	Autori	Jurnal	Scor relativ de influenza 2013	Factor de impact 2012/2013
1	TNF-A; GENE KNOCKOUT IN TRIPLE NEGATIVE BREAST CANCER CELL LINE INDUCES APOPTOSIS..	Pileczki V, Braicu C, Gherman CD, Berindan-Neagoe I.	INT J MOL SCI. 2012 DEC 24;14(1):411-20. DOI: 10.3390/IJMS14010411	2.088	2.464
2	QUANTITATIVE MRNA EXPRESSION OF GENES INVOLVED IN ANGIOGENESIS, COAGULATION AND INFLAMMATION IN MULTIFORME GLIOBLASTOMA TUMORAL TISSUE VERSUS PERITUMORAL BRAIN TISSUE: LACK OF CORRELATION WITH CLINICAL DATA.-	Berindan-Neagoe I, Chiorean R, Braicu C, Florian IS, Leucuta D, Crisan D, Cocis A, Balacescu O, Irimie A.	EUR CYTOKINE NETW. 2012 JUN;23(2):45-55_2012 , doi: 10.1684/ecn.2012.0302.	0.642	1.896
3	NOVEL CELLULAR AND MOLECULAR APPROACHES TO STRATIFICATION AND TREATMENT OF COLORECTAL -	Miron N, Susman S, Balacescu O, Buiga R, Berindan-Neagoe I, Cristea V, Balacescu L, Manolescu V, Ciuleanu TE	J GASTROINTESTIN LIVER DIS.2012 DEC;21(4):413-21.	0.720	1.855

4	NON-CODING RNAS AS THERANOSTICS IN HUMAN CANCERS.-	Redis RS, Berindan-Neagoe I , Pop VI, Calin GA	J CELL BIOCHEM. 2012 MAY;113(5):1451-9. DOI: 10.1002/JCB.24038.	1.097	3.062
5	PATHOGENIC INTRONIC AND DELETERIOUS BENIGN VARIANTS: TWO EXTREMES IN CANCER PREDISPOSITION MOLECULAR DIAGNOSIS	Lucian Negură, Anca Negură, Andrei Coneac, Ioana Berindan Neagoe , Doina Azoicăi, Alexandru Irimie	REVISTA ROMANA DE MEDICINA DE LABORATOR 12/2012;	-	0.097
6	EFFICIENT SIRNA DELIVERY SYSTEM USING CARBOXYLATED SINGLE-WALL CARBON NANOTUBES IN CANCER TREATMENT. -	Neagoe IB, Braicu C , Matea C, Bele C, Florin G, Gabriel K, Veronica C, Irimie A	J BIOMED NANOTECHNOL. 2012 AUG;8(4):567-74.	1.098	5.256
7	COMBINING THE CHEMOTHERAPEUTIC EFFECTS OF EPIGALLOCATECHIN 3-GALLATE WITH SIRNA-MEDIATED P53 KNOCK-DOWN RESULTS IN SYNERGIC PRO-APOPTOTIC EFFECTS.	Berindan-Neagoe I, Braicu C, Irimie A.	INT J NANOMEDICINE. 2012;7:6035-47.	1.355	3.463
8	EARLY APOPTOSIS	Berindan-Neagoe I, Braicu C,	J NANOSCI NANOTECHNOL. 2012	0.740	1.149

	SIGNALS INDUCED BY A LOW DOSE OF EPIGALLOCATECHIN 3-GALLATE INTERFERE WITH APOPTOTIC CELL DEATH PATHWAYS.	Tudoran O, Balacescu O, Irimie A.	MAR;12(3):2113-9.		
9	EARLY TRANSCRIPTIONAL PATTERN OF ANGIOGENESIS INDUCED BY EGCG TREATMENT IN CERVICAL TUMOUR CELLS.	Tudoran O, Soritau O, Balacescu O, Balacescu L, Braicu C, Rus M, Gherman C, Virag P, Irimie F, Berindan-Neagoie I.	J CELL MOL MED. 2012 MAR;16(3):520-30.	1.957	4.753
10	SCAVENGER RECEPTOR-MEDIATED UPTAKE OF CELL-PENETRATING PEPTIDE NANOCOMPLEXES WITH OLIGONUCLEOTIDES.	Ezzat K, Helmfors H, Tudoran O , Juks C, Lindberg S, Padari K, El-Andaloussi S, Pooga M, Langel U.	FASEB J. 2012 Mar;26(3):1172-80.	4.063	5.704
11	EPIGALLOCATECHIN GALLATE INDUCE CELL DEATH AND APOPTOSIS IN TRIPLE NEGATIVE BREAST CANCER CELLS HS578T.	Braicu C, Gherman C.	J DRUG TARGET. 2012 Nov 19. [Epub ahead of print] PubMed PMID: 23163783.	1.043	2.768

12	SUPERIOR CYTOTOXICITY AND DNA CROSS-LINKS INDUCTION BY OXALIPLATIN VS CISPLATIN AT LOWER CELLULAR UPTAKE IN COLORECTAL CANCER CELL LINE	P. Virag, M. Perde-Schrepler, E. Fischer-Fodor, C. Tatomir, S. A. Dorneanu, V. I. Cernea, A. Irimie.	ANTI-CANCER DRUGS, 2012 Nov;23(10): 1032-8.	0.901	2.232
13	CURRENT STRATEGIES FOR THE PROTECTION, REGENERATION AND REPLACEMENT OF COCHLEAR HAIR CELLS	Perde-Schrepler M, Maniu A, Cosgarea M	J.OTOLARYNGOL. HEAD NECK.SURG., 2012, 41(4): 227-239.	0,48	0,84
14	HETEROCYCLES 27. MICROWAVE ASSISTED SYNTHESIS AND ANTITUMOUR ACTIVITY OF NOVEL PHENOTHIAZINYL-THIAZOLYL-HYDRAZINE DERIVATIVES.	Ignat A, Lovasz T, Vasilescu M, Fischer-Fodor E, Tatomir CB, Cristea C, Silaghi-Dumitrescu L, Zaharia V.	ARCH PHARM (Weinheim). 2012 Jul;345(7):574-83. doi: 10.1002/ardp.201100355. Epub 2012 Apr 25.	1.085	1.54
15	GITR-EXPRESSING REGULATORY T-CELL SUBSETS ARE INCREASED IN TUMOR-POSITIVE LYMPH NODES FROM ADVANCED BREAST CANCER PATIENTS AS	Krausz LT, Fischer-Fodor E, Major ZZ, Fetica B.	INT J IMMUNOPATHOL PHARMACOL. 2012 Jan-Mar;25(1):59-66.	0.47	2,685

COMPARED TO TUMOR-NEGATIVE LYMPH NODES.					
16	CALLUNA VULGARIS EXTRACT MODULATES NF-KB/ERK SIGNALING PATHWAY AND MATRIX METALLOPROTEINASE EXPRESSION IN SKH-1 HAIRLESS MICE SKIN EXPOSED TO ULTRAVIOLET B IRRADIATION	Filip GA, Postescu ID, Tatomir C , Muresan A, Clichici S.	J PHYSIOL PHARMACOL. 2012 Aug;63(4):423-32.	0.687	2.476
17	ACTIVE AND INACTIVE FORMS OF MATRIX METALLOPROTEINASES 2 AND 9 IN CUTANEOUS MELANOMA	Candrea E, Senila S, Tatomir C , Cosgarea R.	INT J DERMATOL. 2012 Oct 5. doi: 10.1111/j.1365-4632.2012.05772.x. [Epub ahead of print]	0,873	1.342
18	MODULATION OF DOXORUBICIN-INDUCED OXIDATIVE STRESS BY A GRAPE (VITIS VINIFERA L.) SEED EXTRACT IN NORMAL AND TUMOR CELLS.	Postescu ID, Chereches G, Tatomir C , Daicoviciu D, Filip GA.	J MED FOOD. 2012 Jul;15(7):639-45. doi: 10.1089/jmf.2011.0291. Epub 2012 Apr 20.	1,173	1.642
19	METFORMIN PLUS PIAF COMBINATION CHEMOTHERAPY FOR	Petrushev B, Tomuleasa C, Soritau O , Aldea M, Pop T, Susman S, Kacso G, Berindan I ,	EXP ONCOL. 2012;34(1):17-24.	0	1.7

	HEPATOCELLULAR CARCINOMA.	Irimie A , Cristea V.			
20	GOLD NANOPARTICLES CONJUGATED WITH CISPLATIN/DOXORUBICIN/CAPECITABINE LOWER THE CHEMORESISTANCE OF HEPATOCELLULAR CARCINOMA-DERIVED CANCER CELLS.- J	Tomuleasa C , Soritau O , Orza A, Dudea M, Petrushev B, Mosteanu O, Susman S, Florea A, Pall E, Aldea M, Kacso G , Cristea V, Berindan-Neagoe I , Irimie A	J GASTROINTESTIN LIVER DIS. 2012 JUN;21(2):187-96. PMID: 22720309	0.720	1.855
21	PARANEOPLASTIC SYNDROMES WITH CONNECTIVE TISSUE INVOLVEMENT. IT'S NOT ALWAYS LUPUS !	T Timis, C Berce, A Duarte-Garcia, B Petrushev, V Cristea, C Tomuleasa	JOURNAL OF THE BALKAN UNION OF ONCOLOGY 2012, 17:417-421.	0.162	0.761
22	THE COLORECTAL CANCER STEM-LIKE CELL HYPOTHESIS. A PATHOLOGIST'S POINT OF VIEW	S Susman, C Tomuleasa , O Soritau, D Rus-Ciuca, J-C Sabourin, F Bibeau, A Irimie, R Buiga	JOURNAL OF THE BALKAN UNION OF ONCOLOGY, 2012, 17(2):230-236	0.162	0.761
23	MICRORNA-21 INHIBITS SERPINI 1, A GENE WITH NOVEL TUMOR SUPPRESSIVE EFFECTS IN GASTRIC CANCER	Sumitaka Yamanaka, Alexandru V Olaru, Delgermaa Luvsanjav, Fangmei An, Zhe Jin, Rachana Agarwal, Ciprian Tomuleasa , Irinel Popescu, Sorin Alexandrescu, Delia Dima , Mihaela Chivu-	EUROPEAN JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2012, 24(3):346-347	0.744	1.915

		Economescu, Elizabeth A. Montgomery, Michael Torbenso, Christine Vazquez, Stephen J Meltzer, Florin M Selaru			
24	ROZROLIMUPAB, A MIXTURE OF 25 RECOMBINANT HUMAN MONOCLONAL RHD ANTIBODIES, IN THE TREATMENT OF PRIMARY IMMUNE THROMBOCYTOPENI A.	Robak T, Windyga J, Trelinski J, Von Depka Prondzinski M, Giagounidis A, Doyen C, Janssens A, Alvarez-Román Mt, Jarque I, Loscertales J, Rus Gp, Hellmann A, Jêdrzejczak Ww, Kuliczkowski K, Golubovic Lm, Celeketic D, Cucuianu A , Gheorghita A, E, Lazaroiu M, Shpilberg O, Attias D, Karyagina E, Svetlana K, Vilchevska K, Cooper N, Talks K, Prabhu M, Sripada P, Bharadwaj Tp, Næsted H, Skartved Nj, Frandsen Tp, Flensburg Mf, Andersen Ps, Petersen J.	BLOOD, 2012,120, 3670-6.	4.380	9.060
25	LONG TERM REMISSION AFTER TREATMENT WITH RITUXIMAB IN A CASE OF THROMBOTIC THROMBOCYTOPENIC PURPURA.	Dima D, Frinc I, Patiu M, Cucuianu A.	ROM REV LAB MED. 2012, 20, 4: 337-341	-	0.097
26	RSV INFECTION MODULATES IL-15 PRODUCTION AND	Zdrenghia MT , Telcian AG, Laza-Stanca V, Bellettato CM, Edwards MR, Nikonova A,	EUR RESPIR J. 2012, 39, 712-20.	2.768	6.355

	MICA LEVELS IN RESPIRATORY EPITHELIAL CELLS.	Khaitov MR, Azimi N, Groh V, Mallia P, Johnston SL, Stanciu LA.			
27	SYSTEMIC SCLEROSIS-POLYMYOSITIS OVERLAP SYNDROME ASSOCIATED WITH AUTOIMMUNE HEPATITIS AND CEREBRAL VASCULITIS.	Pamfil C, Zdreghea MT , Mircea PA, Manzat Saplacan RM, Rednic N, Rednic S.	J GASTROINTESTIN LIVER DIS. 2012, 21, 317-20.	0.720	1.855
28	IMMUNOLOGICAL PATHWAYS IN VIRUS-INDUCED COPD EXACERBATIONS: A ROLE FOR IL-15.	Zdreghea MT , Mallia P, Johnston SL.	EUR J CLIN INVEST. 2012, 42, 1010-5.	2.183	3.365
29	THYROID CANCER IN CHILDREN: A 20-YEAR STUDY AT A ROMANIAN ONCOLOGY INSTITUTE.	Piciu D, Piciu A, Irimie A	ENDOCR J. 2012 Jun 30;59(6):489-96.	0.738	2.228
30	CEREBRAL FALSE-POSITIVE RADIOIODINE UPTAKE	Piciu, D., Piciu, A. & Irimie, A.	ACTA ENDOCRINOLOGICA- BUCHAREST, 2012 vol. 8, no. 3, pp. 495-495	0.020	0.45

31	BONE-RELATED COMPLICATIONS AND QUALITY OF LIFE IN ADVANCED BREAST CANCER: RESULTS FROM A RANDOMIZED PHASE III TRIAL OF DENOSUMAB VERSUS ZOLEDRONIC ACID.	Martin M, Bell R, Bourgeois H, Brufsky A, Diel I, Eniu A , Fallowfield L, Fujiwara Y, Jassem J, Paterson AH, Ritchie D, Steger GG, Stopeck A, Vogel C, Fan M, Jiang Q, Chung K, Dansey R, Braun A.	CLIN CANCER RES. 2012 SEP 1;18(17):4841-9. EPUB 2012 AUG 14.	3.458	7.837
32	A phase II multicenter study of two different dosages of pemetrexed given in combination with cyclophosphamide as first-line treatment in patients with locally advanced or metastatic breast cancer.	Dittrich C, Solska E, Manikhas A, Eniu A , Tjulandin S, Anghel R, Musib L, Frimodt-Moller B, Liu Y, Krejcy K, Láng I.	CANCER INVEST. 2012 May;30(4):309-16. doi: 10.3109/07357907.2012.657812. Epub 2012 Apr 2.	0.864	2.238
33	Bone-related complications and quality of life in advanced breast cancer: results from a randomized phase III trial of denosumab versus zoledronic acid.	Martin M, Bell R, Bourgeois H, Brufsky A, Diel I, Eniu A , Fallowfield L, Fujiwara Y, Jassem J, Paterson AH, Ritchie D, Steger GG, Stopeck A, Vogel C, Fan M, Jiang Q, Chung K, Dansey R, Braun A	CLIN CANCER RES. 2012 Sep 1;18(17):4841-9. Epub 2012 Aug 14.	3.458	7.837
34	A placebo-controlled, randomized phase II study of maintenance enzastaurin following whole brain radiation therapy in the treatment of	Bjørn H Grønberg; Tudor Ciuleanu ; Oystein Fløtten; Aija Knuuttila; Edvard Abel; Seppo W Langer; Kurt Krejcy; Astra M Liepa; Maria Munoz; Marjo Hahka-Kemppinen; et al.	LUNG CANCER 78, 63 (2012)	1.354	3.392

brain metastases from lung cancer.

35	Intracellular signalling via the AKT axis and downstream effectors is active and prognostically significant in cancer of unknown primary (CUP): a study of 100 CUP cases.	V Golfopoulos; G Pentheroudakis; A Goussia; V Siozopoulou; M Bobos; D Krikelis; A Cervantes; T Ciuleanu ; M Marselos; G Fountzilias; et al.	ANN. ONCOL. 23, 2725 (2012)	2.692	7.384
36	Sunitinib plus erlotinib for the treatment of advanced/metastatic non-small-cell lung cancer: a lead-in study.	R Blumenschein; Tudor Ciuleanu ; Francisco Robert; Harry J M Groen; Tiziana Usari; Ana Ruiz-Garcia; Lesley Tye; Richard C Chao; Erzsebet Juhasz	J THORAC ONCOL 7, 1406 (2012)	1.964	4.473
37	International, randomized, placebo-controlled, double-blind phase III study of motesanib plus carboplatin/paclitaxel in patients with advanced nonsquamous non-small-cell lung cancer: MONET1.	Scagliotti GV, Vynnychenko I, Park K, Ichinose Y, Kubota K, Blackhall F, Pirker R, Galiulin R, Ciuleanu TE , Sydorenko O, Dediu M, Papai-Szekely Z, Banaclocha NM, McCoy S, Yao B, Hei YJ, Galimi F, Spigel DR-	J CLIN ONCOL. 2012 Aug 10;30(23):2829-36. doi: 10.1200/JCO.2011.41.4987. Epub 2012 Jul 2.	7.605	18.038
38	Profiling immunohistochemical expression of NOTCH1-3, JAGGED1, cMET, and phospho-MAPK in 100 carcinomas of unknown primary.	Dimitrios Krikelis; George Pentheroudakis; Anna Goussia; Vassiliki Siozopoulou; Mattheos Bobos; Dimitrios Petrakis; Aikaterini Stoyianni; Vassilios Golfopoulos; Andres Cervantes; Tudor Ciuleanu ; et al.	CLIN. EXP. METASTASIS 29, 603 (2012)	1.722	3.46

39	Biomarker analysis in a phase III study of pemetrexed-carboplatin versus etoposide-carboplatin in chemo-naïve patients with extensive-stage small-cell lung cancer.	E F Smit; M A Socinski; B P Mullaney; S P Myrand; G V Scagliotti; P Lorigan; M Reck; T Ciuleanu ; J von Pawel; N A Karaseva; et al.	ANN. ONCOL. 23, 1723 (2012)	2.692	7.384
40	Third CECOG consensus on the systemic treatment of non-small-cell lung cancer.	T Brodowicz; T Ciuleanu ; J Crawford; M Filipits; J R Fischer; V Georgoulas; C Gridelli; F R Hirsch; J Jassem; P Kosmidis; et al.	ANN. ONCOL. 23, 1223 (2012)	2.692	7.384
41	Overall survival improvement in patients with lung cancer and bone metastases treated with denosumab versus zoledronic acid: subgroup analysis from a randomized phase 3 study.	Scagliotti GV, Hirsh V, Siena S, Henry DH, Woll PJ, Manegold C, Solal-Celigny P, Rodriguez G, Krzakowski M, Mehta ND, Lipton L, García-Sáenz JA, Pereira JR, Prabhaskar K, Ciuleanu TE , Kanarev V, Wang H, Balakumaran A, Jacobs I.	J THORAC ONCOL. 2012 Dec;7(12):1823-9. doi: 10.1097/JTO.0b013e31826aec2b.	1.964	4.473
42	Induction chemotherapy followed by concomitant radiotherapy and weekly cisplatin versus the same concomitant chemoradiotherapy in patients with nasopharyngeal carcinoma: a randomized phase II study conducted by the Hellenic	Fountzilias; E Ciuleanu ; M Bobos; A Kalogera-Fountzila; A G Eleftheraki; G Karayannopoulou; T Zaramboukas; A Nikolaou; K Markou; L Resiga ; et al.	ANN. ONCOL. 23, 427 (2012)	2.692	7.384

Cooperative Oncology Group (HeCOG) with biomarker evaluation.

<p>43 Aflibercept and Docetaxel versus Docetaxel alone after platinum failure in patients with advanced or metastatic non-small-cell lung cancer: a randomized, controlled phase III trial.</p>	<p>Ramlau R, Gorbunova V, Ciuleanu TE, Novello S, Ozguroglu M, Goksel T, Baldotto C, Bennouna J, Shepherd FA, Le-Guenec S, Rey A, Miller V, Thatcher N, Scagliotti G.</p>	<p>J CLIN ONCOL. 2012 Oct 10;30(29):3640-7. doi: 10.1200/JCO.2012.42.6932. Epub 2012 Sep 10.</p>	<p>7.605</p>	<p>18.038</p>
<p>44 A phase II open-label randomized study to assess the efficacy and safety of selumetinib (AZD6244 [ARRY-142886]) versus capecitabine in patients with advanced or metastatic pancreatic cancer who have failed first-line gemcitabine therapy.</p>	<p>Bodoky G, Timcheva C, Spigel DR, La Stella PJ, Ciuleanu TE, Pover G, Tebbutt NC</p>	<p>INVEST NEW DRUGS. 2012 Jun;30(3):1216-23. doi: 10.1007/s10637-011-9687-4. Epub 2011 May 19. Erratum in: Invest New Drugs. 2012 Jun;30(3):1272-3.</p>	<p>1.343</p>	<p>3.498</p>
<p>45 Porous c.p. Titanium Using Dextrin as Space Holder for Endosseous Implants. Particulate Science and Technology</p>	<p>Gligor I, Sorita O., Todea M, Berce C, Vulpoi A., Marcu T, Cernea V, Simon S, Popa C.</p>	<p>PARTICULATE SCIENCE AND TECHNOLOGY: AN INTERNATIONAL JOURNAL 2012 DOI:10.1080/02726351.2012.749556</p>	<p>0.442</p>	<p>0.435</p>
<p>46 Randomised phase 3 trial comparing 2 Cisplatin dose schedules in 326 patients with locally</p>	<p>Nagy VM, Ordeanu C, Coza O, Rancea CA, Traila A, Todor N.</p>	<p>INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2012, vol.22(9): 1532-1544</p>	<p>1.149</p>	<p>1.941</p>

advanced squamous cell
cervical carcinoma: long-
term follow-up.

76,765 **173.438**
